We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Pharmaceutical Prod Dev (MM) | NASDAQ:PPDI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 33.24 | 0 | 01:00:00 |
DALLAS, Oct. 4, 2011 /PRNewswire/ -- Goldfarb Branham LLP is investigating whether the board of directors of Pharmaceutical Product Development (NASDAQ: PPDI) violated shareholder protection laws by agreeing to sell the company for $33.25 per share. Concerned investors are encouraged to contact attorney Hamilton Lindley at 877-583-2855 or hlindley@goldfarbbranham.com about their rights and remedies.
"As recently as mid-August, shares of the company were trading at $32.20 per share," securities lawyer Hamilton Lindley said. "Additionally, at least one analyst set a target price of $38.00 per share on the PPDI stock. Our proposed shareholder class action lawsuit seeks to ensure that investors get the most value for their stock in this buyout."
Goldfarb Branham LLP lawyers have significant experience representing shareholders and whistleblowers in securities lawsuits nationwide. Pharmaceutical Product Development stockholders – or anyone with knowledge about this acquisition – should contact lawyer Hamilton Lindley at hlindley@goldfarbbranham.com or 877-583-2855.
Hamilton Lindley
Goldfarb Branham LLP
2501 N. Harwood, Ste. 1801
Dallas, TX 75201
(877) 583-2855 Toll Free Telephone
(214) 583-2233 Local Phone Number
(214) 583-2234 Fax Number
hlindley@goldfarbbranham.com
www.goldfarbbranham.com
SOURCE Goldfarb Branham LLP
Copyright 2011 PR Newswire
1 Year Pharmaceutical Product Developme Chart |
1 Month Pharmaceutical Product Developme Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions